A combination of topical and systemic administration of brimonidine is neuroprotective in the murine optic nerve crush model
Fig 3
Photomicrograph illustrating immunofluorescence staining of mouse retinal whole-mount in experimental ONC groups, representing retinal cell densities in the experimental ONC and control groups.
A, B, C, D: Grey scale DAPI nuclear marker representing all cells of retinal ganglion cell layer; E, F, G, H ‐ NeuN-stained retinal ganglion cells and amacrine cells in green; I, J, K, L–retinal astrocytes (in red) labeled with antibodies against GFAP. A, E, I: retinal whole-mount explan from control group (without ONC); B, F, J: retinal whole mount explant from ONC/saline drop + IP group; C, G, K: retinal whole mount in ONC/BMD drop group; D, H, L: retinal whole mount in ONC/BMD drop + IP group. ONC, optic nerve crush; BMD, brimonidine; IP, intraperitoneal; DAPI, 4′,6-diamidino-2-phenylindole; NeuN, neuronal nuclei; GFAP, glial fibrillary acidic protein. Scale bar– 50 μm.